Information Provided By:
Fly News Breaks for June 3, 2015
DSCI
Jun 3, 2015 | 07:44 EDT
Canaccord would be buyers on the dip of Derma Sciences as they believe confusion on the timeline for Aclerastide has created a buying opportunity. The firm also sees its investments in distribution accelerating growth in its advanced wound care business as well as its cash position being sufficient to get beyond the data readout. Canaccord reiterated its Buy rating and $18 price target on Derma Sciences shares.
News For DSCI From the Last 2 Days
There are no results for your query DSCI